Furthermore, they found that having a germline mutation was associated with a significantly increased risk of prostate cancer metastases (varying from a nonsignificant relative risk (RR) for ATM mutation (RR: 1.6 (95% CI: 0.8–2.8) to highly significant for individuals with BRCA 2 mutations (RR: 26.7 (95% CI: 18.9–36.4)). Here, ATM is linked to prostate cancer.